Evidence map›Paper›PMID 40999524›Full record

ReviewContraception and reproductive medicine2025

Mesenchymal stem cells and platelet rich plasma in the treatment of premature ovarian insufficiency: a scoping review.

Jack Gemayel, Frédéric Harb, Farah Karam, Donna Tahan, Monique Younes, Yvanna Saliba, Diana Chaker, Ahmad Ibrahim, Albert Azar, Mustapha Chaaban and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Contraception and reproductive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jack GemayelFaculty of Health Sciences, University of Balamand, P.O.Box: 55251, Sin El Fil, Lebanon.
Frédéric HarbFaculty of Medicine and Medical Sciences, University of Balamand, P.O. Box 100, Tripoli, Lebanon.
Farah KaramFaculty of Medicine and Medical Sciences, University of Balamand, P.O. Box 100, Tripoli, Lebanon.
Donna TahanFaculty of Medicine and Medical Sciences, University of Balamand, P.O. Box 100, Tripoli, Lebanon.
Monique YounesFaculty of Medicine and Medical Sciences, University of Balamand, P.O. Box 100, Tripoli, Lebanon.
Yvanna SalibaFaculty of Medicine and Medical Sciences, University of Balamand, P.O. Box 100, Tripoli, Lebanon.
Diana ChakerReviva Stem Cell Platform for Research and Applications Center, Bsalim, Lebanon.
Ahmad IbrahimFaculty of Medicine and Medical Sciences, University of Balamand, P.O. Box 100, Tripoli, Lebanon.
Albert AzarReviva Stem Cell Platform for Research and Applications Center, Bsalim, Lebanon.
Mustapha ChaabanFaculty of Medicine and Medical Sciences, University of Balamand, P.O. Box 100, Tripoli, Lebanon.
Alain CheblyCenter Jacques Loiselet for Medical Genetics and Genomics (CGGM), Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Khalil AkouchReviva Stem Cell Platform for Research and Applications Center, Bsalim, Lebanon.
Charbel KhalilReviva Stem Cell Platform for Research and Applications Center, Bsalim, Lebanon. c.khalil@revivamedical.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Premature ovarian Insufficiency (POI) is characterized by amenorrhea, hypergonadotropic hypogonadism, estrogen deficiency, and reduced follicle counts leading to infertility under the age of 40. It occurs in 1 to 3% of women. Several therapeutic strategies have been explored in clinic for POI. Platelet Rich Plasma (PRP) a blood product applied in regenerative medicine, which is based on the releasing of the growth factors present in platelet. Mesenchymal Stem Cells derived from Bone marrow, adipose tissue or cord blood tissue are undifferentiated cells with a potential for self-renewal and differentiation into multiple mature cell type. Mesenchymal stem cells secretome can stimulate cellular process and activate multipotent stem cells to generate new younger tissue and blood vessels relevant to ovarian rejuvenation and endometrial regeneration. This review provides a critical analysis on novel treatments that have not achieve routine clinical practice status yet but have recently emerged as promising potential therapy.

Indexed as

Mesenchymal stem cellsPlatelet rich plasmaPremature ovarian insufficiencySecretomeStem cell therapy

Identifiers

PMID40999524
PMCPMC12465821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.